Objective: The incidence of urinary bladder cancer (UBC) has increased in Sweden despite decreased smoking, indicating that other factors might be associated. The increased use of statin medication for elevated blood lipids might be one such influencing factor. The aim of the present study was to assess whether statins are afflicted with an increased incidence of UBC. Results: Statins were more frequently used in patients with UBC (33.8%) than in controls (29.8%, p<0.0001). The use of statins was afflicted with a 23% increased odds ratio (OR) for UBC (OR 1.23 (1.19-1.27), p<0.001). Subgroup analyses showed that an increased OR was found in non-muscle invasive UBC only. There was a tendency that OR was stronger for men and for younger patients. Limitations include its retrospective register-based design and potential risk of bias of confounding factors, such as smoking and body mass index.
Introduction
During the last decades, there has been an increasing interest in public health and disease prevention by lifestyle alterations. In addition, different medications have been widely used to reduce risks of different diseases. One such preventive treatment is the use of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins). This group of drugs has become one of the most prescribed drugs worldwide after their introduction more than two decades ago. Statin therapy has been shown to be effective in lowering low-density lipoprotein cholesterol (LDL-C) levels, as well as triglyceride levels. [1] A Cochrane review in 2013, based on 18 randomized trials, found that statin therapy significantly reduced all-cause mortality, fatal and non-fatal cardiovascular events, and stroke. [2] In a meta-analysis study on 26 trials, an overall reduction in all-cause mortality of 10% for every 1.0 mmol/L reduction in LDL-C levels was revealed. [3] In addition, there were significant reductions in both myocardial infarction and stroke events. [3] Based on solid evidence supporting its use, the guidelines have recommended statin therapy to reduce atherosclerotic cardiovascular risk in adults. [4] There has been a continuous increase in the age-standardized incidence of urinary bladder cancer (UBC) during the last two decades in Sweden according to the National Board of Health and Welfare in Sweden.
[5] The reason for this increase is unclear since the use of cigarette smoking, the most established risk factor for UBC, has substantially decreased in Sweden, as well as in Norway, during the last decades, especially among men. [6, 7] In addition, occupational exposure, another established risk factor for UBC, has been reduced due to occupational regulations and increased awareness of different risk factors. Other factors appear to be involved in the increased incidence of UBC. Change in lifestyle and nutrition might be such factors. Metabolic syndrome is also associated with an increased risk of UBC [8] , as well as with other malignancies. [9] One lifestyle medication is the increased prescription of statins in the population for elevated blood lipids. However, concerns have been raised on not only the overprescription of statins but also the risk for potential adverse effects including musculoskeletal symptoms, diabetes, and hepatic and renal dysfunction. [10] Some published data indicate a reduced risk for malignancies by the use of statins in humans and increased overall survival. [11] In contrast, Vinogradova et al. [12] found an elevated risk for UBC in patients on statin treatment.
The objective of the present study was to assess whether the use of statin medications is afflicted with an increased incidence of UBC, evaluating a total nationwide population of patients with primary diagnosed UBC.
Material and methods

Study design and data sources
This register-based study included data from three national Swedish registries, including Swedish National Register of Urinary Bladder Cancer (SNRUBC), National Population Register, and Swedish Prescribed Drug Register. Inclusion criterion was patients with new diagnosed UBC between 2005 and 2014 registered in the SNRUBC. Virtually all patients with new diagnosed UBC are registered in the SNRUBC with a 98% coverage rate compared with the Swedish National Cancer Register, in which registration of all new diagnosed neoplasms is mandatory by law. Statin prescription was defined as any medication prescribed before the diagnosis of UBC with the Anatomical Therapeutic Classification (ATC) code C10A. Diabetes medication was defined by the ATC codes A10A and A10B prescribed before the diagnosis of UBC. For each of the patients collected from the SNRUBC, 10 control individuals were matched from the National Population Register, with the same age, sex, and living in the same county. The patient population and the control persons were merged with data from the National Cancer Register and the Swedish Prescribed Drug Register (July 2005-onwards) using personal identification numbers. All data were made anonymous before use in the analysis. The study was approved by the institutional review board and the regional ethical board (Dnr 2013-62-31M and amendments: Dnr 2013-400-32M, Dnr 2014-367-32M, and Dnr 2014-384-32M).
Statistical analysis
All data were summarized descriptively. Categorical variables were expressed as frequency and relative frequency. Continuous variables were expressed as mean, median, and range. The chi-square test was used to compare groups. When odds ratio (OR) between cases and controls are evaluated, the CochranMantel-Haenszel test was used. All tests were two-sided. A p value <0.05 was considered as statistically significant. In the subgroup analysis of non-diabetes, only patients with UBC and their controls, who did not use diabetes medications, were included in the analysis. Table 1 . The control persons, collected from the National Population Register in Sweden, comprised 229,326 individuals (Table 2 ).
Results
Patients
Statin and diabetes medication
Among the 22,936 patients with UBC, 7754 (33.8%) patients were treated with statins before the diagnosis of UBC, significantly more frequently than 68,247 of the 229,326 controls (29.8%, p<0.0001). In addition, diabetes medication was more frequently used among patients with UBC (2987, 13.0%) than among the control population (25,673, 11.2%, p<0.0001). The distribution of statin use in patients with UBC in relation to patient and tumor characteristics is shown in Table 3 . The use of statin medication was significantly associated with the risk of occurrence of UBC (OR 1.23 (1.19-1.27), p<0.001, Table  3 ). This OR was observed only in the non-muscle invasive UBC (1.31 (1.26-1.35)), whereas there was no increased OR in patients with muscle invasive UBC. As shown in Table 3 , a significant OR was also shown for all non-muscle invasive TNM stage groups.
Further, there were significant increased ORs of statin medication in all age groups analyzed, albeit the youngest patients had the highest OR (1.36 (1.26-1.47)), and the oldest patient group the lowest OR (1.16 (1.09-1.22), Table 3 ). Among genders, both males and females had significant ORs, but there was stronger OR for men than for women (Table 3 ). After exclusion of all patients and control individuals with diabetes, the ORs remained similar, indicating that diabetes mellitus had less or no impact on the risk for UBC (Table 3) . When analyzing the impact of diabetes in patients with non-muscle invasive UBC only, there were merely limited differences in ORs as compared with the ORs analyzed in all patients (data not shown). In a subgroup analysis of 12,144 patents primarily diagnosed between 2010 and 2014, there were 5041 (42%) patients treated with statins during this period. When dividing these patients into those treated with statins for >5 years and those treated <5 years, we found similar ORs in these groups with ORs of 1.26 and 1.23, respectively (data not shown).
Discussion
In the present study, using a nationwide population-based cohort, we found that patients on statin medication were significantly associated with an increased risk to be diagnosed with UBC. This association was independent of diabetes mellitus and indicates a relationship between statin medication and diagnosis of UBC, although no causality can be confirmed. Confounding factors cannot be overruled as smoking and body mass index (BMI). These factors were not registered in the SNRUBC.
The public health registries in Sweden provide a unique opportunity to perform truly population-based studies. Virtually all patients with new diagnosed UBC during the study period were included through the SNRUBC. [13] By linking these patients with UBC to two other national Swedish registries, we could design a large control population, matched to the patients on gender, age, and county of living from the entire population of patients in Sweden. The use of statin and diabetes medications was linked to patients with UBC, as well as to the control population, by using the Swedish Prescribed Drug Register.
We found a significant increased risk for the occurrence of UBC for individuals treated with statins. That finding remained when adjusted for diabetes, one known confounding risk factor promoting UBC. [14] One novel finding in our study is that significant ORs were observed in patients with non-muscle invasive UBC only, whereas no association was found in muscle invasive and The Cochran-Mantel-Haenszel test was used to evaluate odds ratios and confidence intervals in all cases and controls, subgroup of cases, and control individuals without diabetes, respectively. Subgroup analysis was done based on age at diagnosis, whether muscle invasive UBC, and gender and grouped on TNM stage and tumor grade.
ages. The lower OR in the elderly might be due to a possible accumulation of other risk factors. Our finding with an increased risk for UBC in statin users was supported by a previous nested case-control study finding an OR of 1.16. [12] In their study, Vinogradova et al. [12] found a significant increased risk for UBC but only after >48 months of statin medication. In a subgroup analysis in the present study, we could not duplicate their results since we found no significant difference in risk between patients treated with statins for more or less than 5 years. Our results were further supported by a retrospective study on long-term chemoprevention with statin and aspirin, aiming to reduce the risk of tumor recurrence in patients with non-muscle invasive UBC. Patients treated with statins only or with a combination of aspirin and statin showed increased recurrence rates. In contrast, long-term treatment with aspirin only reduced the risk of tumor recurrence. [15] These results indicate a tumor-promoting effect of statin medication in UBC, supporting our findings.
The reason for this increased risk of UBC in patients treated with statins is unclear. It can instead be due to confounding factors associated with the contemporary use of statins. Hypothetically, statins can affect the urothelial bladder cells by metabolic changes in the mitochondria both through the blood circulation and by a concentration of statins in the urinary bladder after excretion. The initial positive effects of statin medications in lowering LDL-C and triglyceride levels through the mitochondria might be different from the long-term adverse effects. Thus, long-standing metabolic changes in the cell mitochondria might be one plausible reason for the increased risk of UBC. [16] [17] [18] In contrast to the results observed in the present study, as well as the results in the study by Vinogradova et al. [12] , Zhang et al. [19] found no association between statin use and risk of UBC in a meta-analysis study. Their study was based on three randomized controlled trials, five cohorts, and five case-control studies with a substantial heterogeneity between the materials. For other malignancies, such as hematological, liver cancer, and malignancies in postmenopausal women, in contrast, statin treatment was associated with a reduced incidence. [20] [21] [22] In some other studies, such as the Cochrane review, the Cholesterol metaanalyses, and the West Scotland Coronary Prevention Study, no difference in the occurrence of malignancies was observed after long-term statin therapy. [2, 3, 23] In the study by Vinogradova et al. [12] , it was concluded that prolonged use of statins may be associated with an increased risk of colorectal cancer, UBC, and lung cancer but found no overall cancer risk. In patients with non-muscle invasive UBC, Richard et al. found that cumulative statin use is associated with improved overall survival, but not with cancer-specific survival. [24] These findings were further verified in a meta-analysis study of urological malignancies displaying an advantage in the overall survival in patients with UBC and renal cell carcinoma on statin medication. [25] The present study has several limitations. These include its register-based retrospective nature and the potential risk of bias of confounding factors, such as metabolic disorders, obesity, hip-to-waist ratio, and lifestyle. It cannot be ruled out that the found increased risk for UBC of statins is due to confounders. The absence of differences in ORs between patients with or without diabetes indicates that diabetes or the use of diabetes medication appears not to be an important confounder. In the present study, no data are available on smoking, a factor well associated with cardiovascular events and onset of UBC. [26] The general decline in smoking habits during the last decades in Sweden, especially in men (between 13% and 21% in 2004), has not been followed by a decreased UBC incidence. However, the impact of smoking on the risk for onset of UBC in the present study cannot be overruled. If smokers in general are more frequently prescribed with statins than non-smokers, the increased ORs in our study might instead depend on smoking. However, in the study by Vinogradova et al. [12] , statin medication remained with an increased OR after adjusting for smoking, as well as diabetes, rheumatoid arthritis, hypertension, and BMI. Other confounders, such as obesity and metabolic syndrome, appear not to be important for the found increased risk of statins in the present study since we found no association between diabetes, a marker for metabolic syndromes, and increased risk for UBC. One of the advantages of the study is the large population of patients and their controls, comprising >250,000 individuals. Furthermore, since virtually all patients nationwide with new diagnosed UBC were included in the study, any risk for selection bias was reduced. Additionally, all prescriptions of statin and diabetes medication were available for all patients and control individuals through the Swedish Prescribed Drug Register.
In conclusion, this nationwide register study of the Swedish population suggests an association between statin medication and occurrence of diagnosis of UBC. The influence of confounding factors, especially smoking, cannot be overruled. This association of statins and UBC was limited to non-muscle invasive UBC only. Furthermore, there was a tendency for higher risk in younger than in older patients. The risk was independent of diabetes mellitus. Our results merit further studies to evaluate the possible drawbacks of medication to prevent lifestyle alterations. Informed Consent: Since all data were made anonymous before any use in the study, the ethical board approaved that the study was performed without any consent from neither patients, nor control individuals who participated in this study. 
